MedTrace Logo

Post-Market Optimization Study of the EMPOWER® RF Catheter to Ablate Soft Tissue Lesions in the Lung

NCT04131777 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2020-03-27

No results posted yet for this study

Summary

A post-market study to assess the performance and safety of a RF ablation catheter to bronchoscopically ablate lung lesions will be evaluated in patients with confirmed diagnosis of non-small cell lung cancer or metastatic lung lesions who are scheduled for surgical resection.

Conditions

  • Lung Diseases

Interventions

DEVICE

Radiofrequency (RF) catheter

A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation

Sponsors & Collaborators

  • Uptake Medical Technology, Inc.

    collaborator INDUSTRY

  • Broncus Medical Inc

    lead INDUSTRY

Principal Investigators

  • Felix J Herth, MD, PhD · Heidelberg University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2020-08-31
Completion
2020-11-30
FDA Device
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04131777 on ClinicalTrials.gov